Hematologic Neoplasms Clinical Trial
Official title:
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
This study will evaluate the validity of using a survey to quantify patient preferences at the point-of-care and the potential effectiveness of the survey to improve goal-concordant care. The primary hypothesis is that by identifying the strength of patient preferences for outcomes with this survey clinicians will be able to improve goal-concordant care by aligning clinical recommendations with patients' preferences. This study will have 50 patients with newly diagnosed hematologic malignancy complete the survey throughout their disease course (up to 2 years) and conduct qualitative interviews with a subset (n = 20) of participants. The information obtained from these participants will be used to refine the survey. Interviews with oncologists and palliative care specialists (up to 10) will inform implementation.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03483194 -
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03735992 -
Mind-body Medicine for Patients With Malignant Hematological Diseases
|
N/A | |
| Recruiting |
NCT04959175 -
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04275154 -
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
|
||
| Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
| Completed |
NCT00389428 -
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.
|
Phase 1 | |
| Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
| Recruiting |
NCT00071045 -
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
|
||
| Not yet recruiting |
NCT05054231 -
Immunological Profile for Patients Treated With CAR-T Cells
|
N/A | |
| Completed |
NCT02650791 -
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
|
Phase 3 | |
| Completed |
NCT01362179 -
National Marrow Donor Program Long-Term Donor Follow-Up
|
||
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Terminated |
NCT03648372 -
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03320915 -
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
|
Phase 2 | |
| Recruiting |
NCT06422533 -
Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients
|
N/A | |
| Terminated |
NCT02895529 -
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
|
Phase 4 | |
| Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT03083327 -
Prophylactic Early PN in HPT/BMT
|
N/A | |
| Recruiting |
NCT03743480 -
Early Palliative Care and Hematological Cancer Patients
|
N/A |